Sell Jazz Pharmaceuticals (NSDQ: JAZZ)

Jazz is up almost 30% since our February 2017 entry point. Although the stock has not hit my original $198 target, I suggest booking this robust gain.

Recent commentary from the FDA regarding issues with branded drug companies thwarting efforts of new generic entrants may drag Jazz down. I know of no evidence of Jazz blocking competitors but know how quickly sellers can appear when this group is under pressure.

I may revisit this name as a long position if the stock falls to more attractive levels.